WeTrade Group, an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, has completed an in-depth discussion of the strategic partnership with Jiqing Biomedical Technology Co. Ltd recently. The companies will sign the official contract soon and Wetrade will take the exclusive sale channel for Jiqing's monkeypox virus test kits globally.

Jiqing, a medical company that has been at the top of the medical industry in China, has changed its development strategy to overseas markets. From the COVID-19 antigen test kits to monkeypox test kits, Jiqing has consolidated the overseas market step by step. Jiqing expects to benefit from the advanced technology and international market channels through partnering with Wetrade.

As a global-oriented development enterprise, Wetrade has been working on discovering overseas business for domestic companies. Wetrade believes that building its own private domain traffic would help Chinese companies carry out business operations in overseas markets easier. In the meantime, it would empower those companies to increase product awareness rapidly, find targeted audiences accurately and accumulate customers efficiently.